# Successful treatment of an elderly patient with relapsed/refractory angioimmunoblastic T-cell lymphoma with the PI3Kδ inhibitor linperlisib: a Case Report

## TL;DR

An elderly patient with aggressive T-cell lymphoma achieved partial remission using linperlisib, a drug that targets a specific pathway and is well-tolerated.

## Contribution

This case report demonstrates linperlisib's effectiveness and safety in treating elderly patients with relapsed/refractory AITL.

## Key findings

- Linperlisib combined with gemcitabine/oxaliplatin induced sustained partial remission in an 80-year-old patient.
- The treatment was exceptionally safe with no grade ≥2 toxicities observed.
- Linperlisib maintenance therapy was well-tolerated in a frail elderly population.

## Abstract

Angioimmunoblastic T-cell lymphoma (AITL), a highly aggressive peripheral T-cell lymphoma (PTCL), carries a poor prognosis in elderly patients due to frequent relapse and limited salvage options after multiline therapy. We present the case of an 80-year-old woman with relapsed/refractory (R/R) AITL who relapsed after CHOP and exhibited resistance to the following sequential therapies: second-line chidamide plus COP and third-line chidamide with mitoxantrone hydrochloride liposome. Molecular analysis revealed DNMT3A and IDH2 mutations, reflecting disease complexity. Salvage therapy with linperlisib, a selective PI3Kδ inhibitor, combined with gemcitabine/oxaliplatin induced sustained partial remission, followed by linperlisib maintenance. The regimen demonstrated exceptional safety, with no grade ≥2 toxicities, even in this frail population. This case highlights the dual role of linperlisib as an effective and well-tolerated therapy for elderly R/R AITL patients who have exhausted prior lines. By precisely targeting PI3Kδ, our findings offer critical real-world evidence to address the unmet need for safe salvage strategies in this vulnerable population.